logo
Campers warned about native Aussie plant with sting 'worse than a snake bite'

Campers warned about native Aussie plant with sting 'worse than a snake bite'

Yahoo20-02-2025

Campers have been warned to stay away from a seemingly harmless-looking plant in the bush after one Aussie explained the pain from its sting was "worse than a snake bite" when he brushed against it recently.
The plant in question is called a Gympie Gympie, and at first glance it looks like any other with its large green leaves. However, it's one of the world's most venomous plants and, in true Australian style, it's widespread throughout thousands of kilometres of the country.
"I can tell you from experience, you do not want to touch it," the avid 4WD driver said. "I only just slightly brushed against it. It was one of the most painful things that I've had in my life."
He claimed the painful feeling lingered in his hand "for months" after making contact with the plant and any time he would scratch his skin, it would "blow up again".
"I would choose getting bitten by an animal over getting stung by Gympie Gympie bush again," he said.
Simply touching the leaves, stems or fruit of a Gympie Gympie is enough for people to get stung. The 'sting' is actually caused by tiny hairs containing toxins, and when these break off into your skin, it causes "incredible pain".
Jarryd Kelly, the Curator Manager for the Royal Botanic Garden in Sydney, told Yahoo News he himself had experienced the pain from a Gympie Gympie sting and it was an "incredibly uncomfortable feeling to the point I wanted to cut my hand off".
"It was an immediate pain which escalated to a feeling of burning or as if I'd dunked my hand into acid," he said. "I started to sweat and felt hot, like I was burning up. It kept intensifying which made me think it would never stop."
😲 Aussie stunned by 'massive' $200 plant find in Bunnings
👀 Brits lose it over 'most dangerous' Aussie import
🌱 Woman finds unexpected intruder in houseplant
The pain escalates rapidly over a period of 20 minutes and "makes the toughest of people fearful as it seems as though it's never going to end". It can take hours, or even days, for the pain to subside.
"I recommend admiring them from a distance," he said, explaining the plants play an important ecological role but "aren't so compatible with humans".
The plant rightfully has a fearsome reputation due to the pain it inflicts, with Cairns mother-of-four Naomi Lewis saying the sting was worse than childbirth after she made contact with a Gympie Gympie last year, 7News reported. Sufferers have even reportedly contemplated taking their own lives.
If stung by a Gympie Gympie, seek medical assistance immediately. It is important not to rub the area as this can break the hairs in your skin, making them difficult to remove.
Gympie Gympie plants are found from the Northern Rivers region of NSW all the way up the east coast to the tip of the Cape York Peninsula in Queensland.
Do you have a story tip? Email: newsroomau@yahoonews.com.
You can also follow us on Facebook, Instagram, TikTok, Twitter and YouTube.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

A second Australian IVF mix-up shakes clinic and industry
A second Australian IVF mix-up shakes clinic and industry

Yahoo

time3 hours ago

  • Yahoo

A second Australian IVF mix-up shakes clinic and industry

By Byron Kaye and Kumar Tanishk (Reuters) -One of Australia's top IVF providers mistakenly implanted a patient with her own embryo instead of her partner's in a second fertility clinic mix-up, heightening concerns about an industry that did not have much active government oversight until recently. Monash IVF said the error took place on June 5 at a clinic in Melbourne but did not provide further details such as how it learned of the bungle or what the couple planned to do next. The company said it was supporting the couple, who it did not identify. It said the patient's embryo was mistakenly implanted under a treatment plan which called for an embryo from the patient's partner to be transferred. The incident builds on a reputational maelstrom for Monash IVF which was already reeling from an April disclosure that an Australian woman had given birth to a stranger's baby after a fertility doctor accidentally implanted the wrong embryo to a patient in Brisbane in 2023. That mix-up sparked concerns about security protocols at IVF clinics and an industry which is only now in the process of being more regulated. Monash claimed the world's first IVF pregnancy five decades ago and is Australia's second-largest IVF provider, carrying out nearly a quarter of the country's 100,000 assisted reproductive cycles a year, according to industry data. "This mix-up, the second reported incident at Monash IVF, risks shaking confidence not just in one provider but across the entire fertility sector," Hilary Bowman-Smart, a researcher and bioethicist at the University of South Australia. Shares of Monash IVF were down 24% by midsession on Tuesday, against a rising broader market. The stock is just over half its value before the April announcement. "We had thought the Brisbane clinic embryo transfer error was an isolated incident," Craig Wong-Pan, an analyst at RBC Capital Markets, said in a client note. "We believe there is now risk of a greater impact of reputational damage and market share losses to MVF's operations." Monash IVF had already hired a lawyer to run an independent investigation after the Brisbane incident, and said on Tuesday it has extended the scope of that investigation. It added that it was installing interim extra verification safeguards to ensure patient confidence. "Whilst industry-leading electronic witness systems ... are being rolled out across Monash IVF, there remains instances and circumstances whereby manual witnessing is required," the company said. It said it had reported the Melbourne incident to state regulator the Victorian Department of Health and industry licencing body the Reproductive Technology Accreditation Committee (RTAC), part of industry group the Fertility Society of Australia. The health department and RTAC were not immediately available for comment. Reports of transferring a wrong embryo are rare, according to fertility experts, and Monash's Brisbane mix-up was widely reported as the first known case of its kind. ($1 = 1.5330 Australian dollars)

Australia's Monash IVF reports second embryo incident in two months
Australia's Monash IVF reports second embryo incident in two months

Yahoo

time6 hours ago

  • Yahoo

Australia's Monash IVF reports second embryo incident in two months

(Reuters) -Australian fertility group Monash IVF on Tuesday reported a new incident related to an embryo transfer, within a couple of months after reporting a similar case where a doctor accidentally implanted the wrong embryo. The latest incident, which occurred on June 5 at the company's Clayton laboratory, has been reported to regulatory bodies and the company's insurer, Monash said, issuing an apology to the impacted couple. The company is also conducting an internal investigation. The firm added that it is implementing additional verification processes and patient confirmation safeguards to prevent similar incidents in the future. The clinic owner in April reported a similar incident where an Australian woman gave birth to a stranger's baby due to a Monash fertility doctor's error. Shares of Monash are down about 31% since the news. The mix-up has drawn attention to an industry that was largely self-regulated until recently and raised concerns about security protocols at IVF clinics. The facilities are regulated by a mix of Australian industry bodies and state government agencies.

Berkshire Hathaway Specialty Insurance Launches Life Science, BioTech & Pharmaceutical (LBP) Management Liability Policy in Australia
Berkshire Hathaway Specialty Insurance Launches Life Science, BioTech & Pharmaceutical (LBP) Management Liability Policy in Australia

Yahoo

time7 hours ago

  • Yahoo

Berkshire Hathaway Specialty Insurance Launches Life Science, BioTech & Pharmaceutical (LBP) Management Liability Policy in Australia

BOSTON & SYDNEY, June 09, 2025--(BUSINESS WIRE)--Berkshire Hathaway Specialty Insurance (BHSI) today announced the introduction of a Management Liability Insurance Policy tailored expressly for Life Science, BioTech and Pharmaceutical (LBP) companies in Australia. "The new LBP Management Liability Policy reflects our commitment to Australia's thriving life sciences community and our deep understanding of the challenges start-ups face at every stage of their journey," said Jessica Jefferies, Underwriting Manager, National Brokers, Executive & Professional Lines, BHSI Australia. "Life Sciences is one of the most promising industries in Australia and we are thrilled to be able to provide an innovative solution to support the industry". BHSI's new LBP Management Liability Insurance Policy is specifically for the R&D ecosystem – all stakeholders in Australia's diverse and energetic life sciences sector. The new product offers enhanced cover tailored for life sciences companies, with coverage not found in standard Management Liability policies. BHSI's solution will extend cover and ensure Directors, Officers, Scientific and Medical Advisory Boards all get the benefit of cover as they develop cutting-edge solutions globally. With an understanding of the funding requirements, the product provides two key elements of protection, extending cover for private capital raisings, and not excluding cover in the event of the Company's insolvency. With many Australian life sciences companies looking abroad for clinical development, BHSI's offering has the ability to extend protection to U.S. exposures, recognising the frequent pursuit of FDA approvals by Australian firms. The new solution expands BHSI's existing Management Liability policy wording for private companies and not-for-profits. BHSI is a leading market for Directors and Officers Liability insurance for ASX-listed life sciences companies in Australia. This launch extends that expertise and forms part of BHSI's strategy to provide tailored support for biotech and pharmaceutical customers from start-up to scale. To learn more, contact Berkshire Hathaway Specialty Insurance Company (incorporated in Nebraska, USA) ABN 84 600 643 034, AFS Licence No. 466713 ( provides commercial property, casualty, healthcare professional liability, executive and professional lines, transactional liability, surety, marine, travel, programs, accident & health, medical stop loss, homeowners, and multinational insurance. The actual and final terms of coverage for all product lines may vary. Berkshire Hathaway Specialty Insurance Company holds financial strength ratings of A++ from AM Best and AA+ from Standard & Poor's. Based in Boston, Berkshire Hathaway Specialty Insurance has offices in Atlanta, Boston, Chicago, Columbia, Dallas, Houston, Indianapolis, Irvine, Los Angeles, New York, Plymouth Meeting, San Francisco, San Ramon, Seattle, Stevens Point, Adelaide, Auckland, Barcelona, Brisbane, Brussels, Calgary, Cologne, Dubai, Dublin, Frankfurt, Hamburg, Hong Kong, Kuala Lumpur, London, Lyon, Macau, Madrid, Manchester, Melbourne, Milan, Munich, Paris, Perth, Singapore, Stockholm, Sydney, Toronto, and Zurich. View source version on Contacts MEDIA CONTACTJoAnn Lee / +1 617.936.2937

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store